ADHD

Though the correlation is concerning for at-risk groups, experts believe it could inform individualized psychiatric care during crises.

The APSARD study finds that most neuropsychological assessment scores did not differ significantly between both in-person and virtual visit modalities.

Methylphenidate has shown promising boosting morning function in pediatric patients with ADHD.

The Child Behavior Checklist may provide invaluable information to clinicians regarding the type and severity of comorbid psychopathologies.

The treatment improves morning function for adolescent ADHD patients.

Dr. David Goodman predicts some patients may improve their organizational skills during the pandemic.

Adults with ADHD may face a number of challenges during the ongoing pandemic.

The virtual conference will feature researchers from the US, Germany, Japan, and more.

When compared to standard care, a new CBT method results in a greater drop in SDQ Impact scores.

The mortality rate was higher in ASD patients with SUD than it was for a control group not suffering from ASD.

Investigators believe using a computational system could allow clinicians to have a better read on which treatments could be effective in adolescents with ADHD.

More studies are needed to examine other methods of ADHD assessments.

Experts expect more individuals to face mental health challenges caused by the events of 2020.

Supernus indicates no efficacy or safety concerns from their pediatric ADHD medication.

A greater number of cumulative days of montelukast use did not increase the risk of ADHD in these patients.

Researchers have been unable to leverage new technology for ADHD screening.

Dr. David Goodman discusses the gaps in ADHD treatment.

It is possible to diagnose patients with ADHD as young as 2 years old.

Treatment for ADHD is similar for adolescents and adult patients.

Dr. David Goodman will present 5 times during NEI about different ADHD issues and topics.

A large portion of communication is non-verbal.

Clinicians rated 82% of the patients receiving the study drug and 46% in the placebo group as either much improved or very much improved on the Clinical Global Impression of Improvement scale.

Attempts to use neuroimaging to screen for ADHD in the past have failed.

Both methylphenidate PRC-063 and lisdexamfetamine led to improved performances for drivers with ADHD.

Precision medicine could have a major impact in ADHD.

ADHD is associated with increased procedures, including blood transfusions, hospital admissions, and emergency department visits.

Screenings for ADHD have not improved in several years.

Medications in psychiatry are often ineffective for patients.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Dr. Cortese discusses how new research can drive changes to ADHD clinical trials.